Eli Lilly is reportedly close to a $2 billion deal with Hong Kong-based Insilico Medicine for exclusive rights to a GLP-1 drug for diabetes, leveraging AI for drug development.
Why it matters
This potential acquisition highlights the growing trend of major pharmaceutical companies investing heavily in AI-driven drug discovery. Insilico Medicine's use of AI in identifying and developing novel therapeutics, like the GLP-1 drug for diabetes, demonstrates the tangible impact of AI on accelerating and improving the efficiency of pharmaceutical R&D, potentially leading to faster patient access to new treatments.
A big drug company might pay $2 billion to get a new diabetes medicine from a startup that uses AI to find drugs. This shows how AI is helping create new medicines faster.
AI chip startup Rebellions has secured $400 million in a pre-IPO funding round, valuing the company at $2.3 billion. The company designs specialized chips for AI inference, aiming to compete with established players like Nvidia.
Read on TechCrunch →Mistral AI secures $830 million in debt financing to establish a data center near Paris, slated for operation by Q2 2026.
Read on TechCrunch →Qodo secures $70 million in funding to develop AI-powered code verification tools, addressing the challenge of ensuring the quality and reliability of AI-generated code.
Read on TechCrunch →